Zimbabwe has turned down a major US healthcare agreement valued at 367 million US dollars (£272m) spanning five years over Washington's insistence on sensitive data.
This move became public following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "skewed".
A government representative later explained that the United States was requesting biological samples for research and profit but was not willing to guarantee the benefits from future vaccines.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued negotiations to secure a deal acceptable to all parties so the country's vital HIV programme can continue.
Broader Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a court blocked a similar deal with the US after legal challenges were raised about the safety of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump argued its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
Based on statements, Sixteen African countries have so far agreed to similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our citizens if a new pandemic arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting structures previously set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to manage future pandemics.
"This mechanism is designed to ensure that when a nation provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to continued dialogue with our American counterparts on how future co-operation could be designed in a way that respects the independence and dignity of each country."
Health Experts Reaction
Medical experts expressed it acknowledged the government's concerns, but suggested that negotiations must proceed since much of the nation's Aids initiatives relied on foreign aid.
"Where specific concerns exist, such as those involving information security or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," it said.
The halted deal underscores the complex challenges between receiving crucial international aid and protecting a country's data in an increasingly data-driven world.